GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

This study tests a combination of hormone-blocking medications (a GnRH agonist plus letrozole) for obese women with early-stage uterine (endometrial) cancer who did not respond to the standard hormone treatment (progestins). The goal is to preserve fertility while still treating the cancer. **You may be eligible if...** - You have well-differentiated stage I endometrial cancer confirmed by hysteroscopy - Your BMI is 30 or above - Imaging shows no spread outside the uterus - You already tried standard progestin therapy for at least 7–10 months without achieving a complete response - You want to preserve your fertility **You may NOT be eligible if...** - Your cancer has spread outside the uterus - You responded completely to progestin therapy - You do not wish to preserve fertility - You have other serious medical conditions that would prevent treatment Talk to your doctor to see if this trial is right for you.